Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News| Cord Blood News 9.17 May 4, 2017 | |
 | |
| |
TOP STORYMast Cells Are Reprogrammed through Repeated Triggering Human cord blood-derived mast cells were treated for two weeks with plate-bound IgG. Investigators observed a dampening of the normal IgG responses with a set of novel genes upregulated. De–novo expressed genes consisted of DHCR7 and DHCR24, key enzymes in the cholesterol pathway. Pathway analysis confirmed an enrichment of genes in this pathway following repeated IgG triggering. The study provides evidence that mast cells are also reprogrammed upon repeated IgG triggering. [Ann Rheum Dis] Abstract | |
| |
| |
PUBLICATIONS(Ranked by impact factor of the journal)The authors compared the prognosis of cyclophosphamide/total-body irradiation (CY/TBI) and high-dose cytarabine (HDCA)/CY/TBI regimens in bone marrow or peripheral blood stem cell transplantation (BMT/PBSCT) for acute lymphoblastic leukemia. The addition of HDCA decreased post-transplant relapse, while significantly increasing non-relapse mortality, and overall survival was not improved. [Br J Haematol] Abstract The role of resveratrol (RV), a natural polyphenol, is well documented, although its role on neurogenesis is still controversial and poorly understood. To decipher the cellular insights of RV on neurogenesis, researchers investigated the potential effects of the compound on the survival, proliferation, and neuronal differentiation of human cord blood-derived mesenchymal stem cells. [Mol Neurobiol] Abstract The authors investigated prophylactic or therapeutic efficacy of human placenta-derived mesenchymal stem cells (hPDSCs) against radiation enteropathy and identified biomarkers predicting a favorable response to stem cell therapy. hPDSCs significantly improved the outcome of mice induced with either radiation enteropathy or lethal radiation syndrome. [Stem Cell Res Ther] Full Article In view of the current interest in exploring the clinical use of mesenchymal stem cells (MSCs) from different sources, scientists performed a side-by-side comparison of the biological properties of MSCs isolated from the Wharton’s jelly, the most abundant MSC source in umbilical cord, with bone marrow-MSCs, the most extensively studied MSC population. [Stem Cell Res Ther] Full Article Investigators compared the effects of human umbilical cord blood–derived mesenchymal stromal cells (hUCB-MSCs) and fibroblasts on diabetic wound healing in vivo. They focused on collagen synthesis and angiogenesis, which are considered to be the important factors affecting diabetic wound healing. In terms of collagen synthesis, the hUCB-MSC group showed the highest collagen level, followed by the fibroblast group and the no-cell group in the second week after implantation. [Cytotherapy] Abstract Aging of Bone Marrow– and Umbilical Cord–Derived Mesenchymal Stromal Cells during Expansion Researchers investigated the effects of long-term in vitro expansion on the stability and function of mesenchymal stromal cells (MSCs). Bone marrow–derived (bm)MSCs and umbilical cord–derived (uc)MSCs showed decreasing proliferative capacity over time, while their telomere lengths and mitochondrial activity remained stable. They showed that after long-term expansion, phenotype of bmMSCs and ucMSCs remains stable and cells exhibit similar immunogenic properties compared with lower passage cells. [Cytotherapy] Abstract The authors genetically engineered human mesenchymal stromal cells (MSCs) to secrete human IL3 and TPO. In vitro, these IL3 and TPO-producing MSCs were superior in expanding human cord blood CD34+ hematopoietic stem/progenitor cells. In vivo, these genetically engineered MSCs maintained their ability to differentiate into bone, adipocytes and various other stromal components. [Exp Hematol] Abstract | |
| |
| |
REVIEWSCord Blood as a Potential Therapeutic for Amyotrophic Lateral Sclerosis Cell therapy using human umbilical cord blood (hUCB) cells may be a promising new treatment for amyotrophic lateral sclerosis (ALS), mainly by providing a protective microenvironment for motor neuron survival. Among multiple advantages, hUCB cells’ production of various anti-inflammatory/growth/trophic factors makes them an attractive cell source for ALS therapy. [Expert Opin Biol Ther] Abstract Visit our reviews page to see a complete list of reviews in the cord blood research field. | |
| |
INDUSTRY NEWSCIRM Announces Leadership Transition The California Institute for Regenerative Medicine (CIRM) announced that its President and Chief Executive Officer, C. Randal Mills, Ph.D., will be leaving to become the next President and CEO of the National Marrow Donor Program®/Be The Match®. Maria Millan, M.D., will succeed Dr. Mills as interim President and CEO of CIRM pending further action by the agency’s Presidential Search Subcommittee and full board. [California Institute for Regenerative Medicine] Press Release Be The Match BioTherapies Announces Collaboration Agreement with Magenta Therapeutics Be The Match BioTherapiesSM announced that it has entered into a strategic partnership with Magenta Therapeutics. The collaboration is intended to support efforts to improve transplant outcomes and expand the application of stem cell transplantation into disease indications that include autoimmunity, serious inherited immune and metabolic disorders, blood defects and blood cancers. [Be The Match BioTherapiesSM] Press Release | |
| |
POLICY NEWSNIH to Limit the Amount of Grant Money a Scientist Can Receive For the first time, the US National Institutes of Health (NIH) will restrict the amount of funding that an individual scientist can hold at any one time, based on a new point system. The move is part of an ongoing effort to make obtaining grants easier for early and mid-career scientists, who face much tougher odds than their more-experienced colleagues. [Nature News] Editorial Researchers Frustrated by Italian Misconduct Probe More than five years ago, Italian police began investigating allegations of research misconduct in papers by Alfredo Fusco, a prominent cancer scientist in Naples. Researchers frustrated by the case’s slow progress have told Nature that there is strong evidence that dozens of papers may contain manipulated data — and that a commercial photography studio was called in to cut and paste images. They say they are speaking out about the magnitude of the allegations because of their increasing impatience with the slow pace of investigations by police and by academic authorities. [Nature News] Editorial
| |
EVENTSNEW 2017 South Central Association of Blood Banks Annual Meeting Visit our events page to see a complete list of events in the community.
| |
JOB OPPORTUNITIESNEW Postdoctoral Position – Mesenchymal Stem Cell (Longboats Explorers Inc.) NEW Senior Research Scientist – Immunotherapy (Anthony Nolan Research Institute) Research Associate – Blood Stem Cells (University of Cambridge) Postdoctoral Position – Leukemia Research (VIB-KU Leuven Center) Postdoctoral Fellow – Cancer Research (German Cancer Research Center) Postdoctoral Fellow – Stem Cell Research (Helmholtz Association) Research Group Leader – Leukemia Research (University Hospital Basel) Full Member Faculty – Hematopoietic Cell Transplant Program (Fred Hutchinson Cancer Research Center) Assistant Member Faculty – Platinum/Immunotherapy (Fred Hutchinson Cancer Research Center) Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
| |
Have we missed an important article or publication in Cord Blood News? Click here to submit! Comments or suggestions? Submit your feedback here. | |
|
